Navigation Links
Verenium To Present At Upcoming Conferences
Date:8/29/2012

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that members of its management team will be presenting at four upcoming conferences.

  • James Levine, President and Chief Executive Officer, will present at the 2012 Modern Energy Forum in Denver, Colorado on Wednesday, September 5, 2012. The presentation is scheduled to begin at 4:20 p.m. MT at the Ritz-Carlton, Denver and will not be webcast.
  • Mr. Levine will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012.  The presentation is expected to begin at 11:15 a.m. ET and will take place at the Waldorf Astoria Hotel in New York City.
  • Mr. Levine will present at the MDB Capital Group's 3rd Annual Bright Lights Conference on Tuesday, September 11, 2012.  The presentation is expected to begin at 10:15 a.m. ET and will take place at the New York Palace Hotel in New York City.
  • Jeff Black, Senior Vice President and Chief Financial Officer, will present at the Wedbush Securities Clean Technology and Industrial Growth Management Access Conference in San Francisco, California on Wednesday, September 12, 2012.  The presentation is expected to begin at 3:05 p.m. PT and will take place at the Westin San Francisco, Market Street.

The live webcast of these presentations may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com. A webcast replay will be available approximately one hour after the live webcast end and will be accessible for 30 days following these conferences. 

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's technology, products and product candidates and product pipeline, lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q . These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com



'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
2. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
5. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
6. PAREXEL International to Present at Robert Baird Healthcare Conference
7. Vermillion to Present at the 2012 Gateway Conference on September 6
8. CVS Caremark To Present At Goldman Sachs 2012 Global Retailing Conference
9. Cynosure Announces Upcoming Conference Presentations
10. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
11. Watson to Present at the Morgan Stanley 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):